Amantadine therapy in parkinsonism.
D000367:Age Factors; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004487:Edema / Q000139:chemically induced; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos; D012737:Sex Factors; D013997:Time Factors
D010276:Parasympatholytics; D010919:Placebos; D000547:Amantadine